Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A home for LASIK comments

This article was originally published in The Gray Sheet

Executive Summary

FDA establishes a dedicated docket for public comments on post-market experience with LASIK laser vision correction surgery, the agency announces Sept. 12. After updating its LASIK Web site and strengthening post-market surveillance activities, FDA says it wants to better understand post-treatment quality-of-life issues. LASIK complications have taken a high-profile in recent months, and on May 19 yet another citizen petition was filed urging FDA to ban the devices (1"The Gray Sheet" March 24, 2008, p. 6). Comments may be submitted to FDA-2008-N-0488 through Sept. 14, 2009
Advertisement

Related Content

Regulatory News In Brief
Post-LASIK Vision Correction Quality-Of-Life Will Be Reviewed By FDA Panel
Post-LASIK Vision Correction Quality-Of-Life Will Be Reviewed By FDA Panel
Advertisement
UsernamePublicRestriction

Register

MT026552

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel